Reported Earlier, AbbVie's Epcoritamab Receives EMA Opinion for Follicular Lymphoma Treatment
Portfolio Pulse from Benzinga Newsdesk
AbbVie's epcoritamab receives a positive opinion from the EMA's CHMP for conditional marketing authorization as a monotherapy for relapsed or refractory follicular lymphoma. The European Commission's decision is expected later this year.
June 28, 2024 | 7:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's epcoritamab has received a positive opinion from the EMA's CHMP for conditional marketing authorization for treating relapsed or refractory follicular lymphoma. This could lead to increased market share and revenue if the European Commission approves it later this year.
The positive opinion from the EMA's CHMP is a significant step towards the approval of epcoritamab in Europe. If the European Commission follows through with approval, it could lead to increased market share and revenue for AbbVie, especially given the unmet need for effective treatments for relapsed or refractory follicular lymphoma.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100